Here’s why the Immutep (ASX:IMM) share price is up today

Immutep has signed a new agreement on a key antibody product.

| More on:
Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price is rising today after news of a deal with a European company.

Shares in Immutep were swapping hands at 47.5 cents in early morning trade, up 1.06%.

Let’s take a look at what may be influencing the Immutep share price today?

What did Immutep announce?

Immutep is a biotech company developing a treatment for autoimmune diseases and cancer.

Today, the company advised it has signed an agreement with Northway Biotech to manufacture an antibody suppressor known as IMP761.

IMP761, currently at the preclinical stage, works to silence memory T cells that gather at disease sites.

The company has tested the product against autoimmune diseases including arthritis to prove the concept.

As part of the agreement with Northway Biotech, the European manufacturer will produce IMP761 in large scale bioreactors.

Once this upscale is complete, the product will be used for Immutep’s clinical trial of IMP761.

Immutep said the production would take place at Northway’s facility in Vilnius, Lithuania. In the future, the agreement may be extended to include commercial supply.

Comment from management

Commenting on the agreement that may be driving the Immutep share price higher, CEO Marc Voight said:

We are very excited to be partnering with Northway Biotech to develop a GMP manufacturing process for IMP761.

We are very pleased to be moving IMP761 towards clinical trials.

Immutep share price snap shot

The Immunotep share price has climbed 10% in the past 12 months, rallying 13% year to date.

The biotech company’s shares dived nearly 21% in the past month but are holding steady in the past week.

In comparison, the S&P/ASX 200 Health Care (ASX:XHJ) index is down 5% today and has risen nearly 2% in the year to date.

Immutep has a market capitalisation of more than $405 million at the time of writing.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

Up 38% in a month, what’s sparking the recent Race Oncology share price run-up?

What a month it has been for Race Oncology shareholders.

Read more »

Three businesspeople leap high with the CBD in the background.
Healthcare Shares

Why is the Nanosonics share price jumping 10% on Wednesday?

Nanosonics shares are jumping on Wednesday...

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Healthcare Shares

Why this broker is tipping the ResMed share price to rise 17%

A leading broker says ResMed shares can rise strongly from here...

Read more »

patient with doctor, medical company, medical insurance
Healthcare Shares

Beating the benchmark: Why this broker is betting on the CSL share price for outperformance

Could plasma demand boost the CSL share price?

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Here’s what happened to the CSL share price in June

CSL shares were relatively positive performers in June...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Up 13% in a month, Polynovo share price bounces back after being dumped from ASX 200

What's going on with the Polynovo share price?

Read more »

health workers shake hands and congratulate each other on good news
Share Gainers

This ASX All Ordindaries healthcare share is ripping 17% higher amid a new contract win

Investors seem to like the contract win from this healthcare player.

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Here’s how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

Read more »